Materials scientists at Rice University and collaborators have developed a material that uses light to break down a range of ...
MedPage Today on MSN
Trial Results Could Shuffle Order of BTK Inhibitors for CLL/SLL
ORLANDO -- In a phase III trial with potential practice-changing implications, the non-covalent Bruton's tyrosine kinase (BTK ...
News-Medical.Net on MSN
Evidence grows for pirtobrutinib as a safer and effective alternative for CLL and SLL
Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms ...
The discovery of a stable single-electron covalent bond between two carbon atoms validates a century-old theory. The discovery of a stable single-electron covalent bond between two carbon atoms ...
The FDA has approved pirtobrutinib (Jaypirca) treatment for adults with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received prior treatment with ...
Researchers said future studies could help refine the use of Jaypirca alone or in combination with other therapies as a frontline treatment. She added that they are also continuing to investigate ...
A new high-throughput study that used publicly available data shows that E. coli proteins containing a structure called a non ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results